Abemaciclib plus endocrine therapy for hormone receptor- positive, HER2-negative, node-positive, high-risk, early breast cancer

被引：1
|
作者：
Nozawa, Kazuki [1 ]
Sawaki, Masataka [1 ]
Iwata, Hiroji [1 ]
机构：
[1] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi 4648681, Japan
来源：
LANCET ONCOLOGY | 2023年 / 24卷 / 03期
关键词：
OPEN-LABEL;
D O I：
10.1016/S1470-2045(23)00014-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E103 / E103
页数：1
相关论文
共 50 条
  • [41] Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
    Shohei Shikata
    Takeshi Murata
    Masayuki Yoshida
    Hiromi Hashiguchi
    Yukiko Yoshii
    Ayumi Ogawa
    Chikashi Watase
    Sho Shiino
    Hirokazu Sugino
    Kenjiro Jimbo
    Akiko Maeshima
    Eriko Iwamoto
    Shin Takayama
    Akihiko Suto
    Scientific Reports, 13
  • [42] Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
    Shikata, Shohei
    Murata, Takeshi
    Yoshida, Masayuki
    Hashiguchi, Hiromi
    Yoshii, Yukiko
    Ogawa, Ayumi
    Watase, Chikashi
    Shiino, Sho
    Sugino, Hirokazu
    Jimbo, Kenjiro
    Maeshima, Akiko
    Iwamoto, Eriko
    Takayama, Shin
    Suto, Akihiko
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [43] A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, including hormone receptor-positive, HER2-negative breast cancer (plus endocrine therapy)
    Yee, Douglas
    Sablin, Marie Paule
    Iwata, Hiroji
    Johnston, Erica L.
    Bogenrieder, Thomas
    Serra, Josep
    Hua, Hairui
    Lo Russo, Patricia
    Prat, Aleix
    CANCER RESEARCH, 2018, 78 (04)
  • [44] Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
    Hamilton, Erika P.
    Kim, Jee Hyun
    Eigeliene, Natalja
    Mavroudis, Dimitrios
    Median, Dragos Mircea
    Marconato, Heloisa
    Shevnia, Serhii
    Ozyilkan, Ozgur
    Puig, Juan Manuel
    Shannon, Catherine M.
    Munoz, Maria
    San Antonio, Belen
    Wei, Ran
    O'Shaughnessy, Joyce
    Johnston, Stephen R. D.
    Guarneri, Valentina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
    Kim, Hee Jeong
    Noh, Woo Chul
    Lee, Eun Sook
    Jung, Yong Sik
    Kim, Lee Su
    Han, Wonshik
    Nam, Seok Jin
    Gong, Gyung-Yub
    Kim, Hwa Jung
    Ahn, Sei Hyun
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [46] Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
    Hee Jeong Kim
    Woo Chul Noh
    Eun Sook Lee
    Yong Sik Jung
    Lee Su Kim
    Wonshik Han
    Seok Jin Nam
    Gyung -Yub Gong
    Hwa Jung Kim
    Sei Hyun Ahn
    Breast Cancer Research, 22
  • [47] Risk of Abemaciclib-induced Liver Injury in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer: A Retrospective Analysis
    Taniguchi, Azusa
    Kittaka, Nobutohi
    Kanaoka, Haruka
    Nakajima, Satomi
    Oyama, Yuri
    Seto, Yukiko
    Soma, Ai
    Kusama, Hiroki
    Watanabe, Noriyuki
    Matsui, Saki
    Nishio, Minako
    Fujisawa, Fumie
    Nakayama, Takahiro
    ANTICANCER RESEARCH, 2022, 42 (12) : 6027 - 6035
  • [48] Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer
    Reinert, Tomas
    de Paula, Bruno
    Shafaee, Maryam Nemati
    Souza, Pedro Henrique
    Ellis, Matthew J.
    Bines, Jose
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [49] Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
    Andrahennadi, Samitha
    Sami, Amer
    Manna, Mita
    Pauls, Mehrnoosh
    Ahmed, Shahid
    CURRENT ONCOLOGY, 2021, 28 (03) : 1803 - 1822
  • [50] monarchE: Abemaciclib plus endocrine Therapy in High-risk Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (03) : 254 - 254
12345